| Literature DB >> 36091164 |
Pi-Xiao Zhou1, Rui-Hao Wang1, Hui Yu1, Ying Zhang1, Guo-Qian Zhang1, Shu-Xu Zhang1.
Abstract
Background: Integration of 4D-CT ventilation function images into esophageal cancer radiation treatment planning aimed to assess dosimetric differences between different functional lung (FL) protection strategies and radiotherapy techniques.Entities:
Keywords: esophageal cancer; four-dimensional CT (4D-CT); functional lung; intensity-modulated radiotherapy (IMRT); volumetric-modulated arc therapy (VMAT)
Year: 2022 PMID: 36091164 PMCID: PMC9459335 DOI: 10.3389/fonc.2022.898141
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Flowchart of the functional lung obtained from 4D-CT. DIR, deformation image registration; VIA, ventilation imaging algorithm.
Figure 2Typical lung ventilation function images generated in 3D-Slicer software. (A) Grayscale image containing the Jacobian value. (B) Defined regions of Jacobian value ≤0.8 (e.g., functional lung). (C) Distribution of functional lungs in the esophageal cancer patient’s anatomical CT.
The dose-volume restrictions of organs at risk (OARs).
| OARs | Restrictions |
|---|---|
| Lungs | V5<65%, V20<30%, V30<20% |
| Heart | V40<40% |
| Spinal cord | Dmax<45Gy |
| Functional lung | V10<20%, V20<10%, V30<5% |
Detailed clinical information of the patients included in the study.
| No. of patients | 15 |
|---|---|
|
| 57.2 (48–68) years |
|
| |
| Men | 14 (93.3%) |
| Women | 1 (6.7%) |
|
| |
| Squamous cell carcinoma | 13 (86.7%) |
| Small-cell carcinoma | 2 (13.3%) |
|
| |
| U+M | 7 (46.7%) |
| M | 3 (20%) |
| M+L | 3 (20%) |
| L | 1 (6.7%) |
| U+M+L | 1 (6.7%) |
|
| 319.7 (161.7–558.3) |
|
| 48.5 (36–60.2) Gy |
|
| |
| IMRT | 12 (80%) |
| VMAT | 3 (20%) |
SD, standard deviation; PTV, planning target volume; CTV, clinical target volume; U, upper thoracic; M, middle thoracic; L, lower thoracic.
Dosimetric parameter comparison for PTV and OARs in different FL-sparing IMRT and VMAT planning.
| OARs | Non-sparing planning | FL-sparing planning | P value |
|---|---|---|---|
| PTV | |||
| Dmax (Gy) | 56.98 ± 8.46 | 58.26 ± 9.01 | 0.005 |
| Dmean (Gy) | 52.42 ± 7.98 | 52.60 ± 8.01 | 0.178 |
| CI | 0.692 ± 0.083 | 0.662 ± 0.098 | 0.024 |
| HI | 1.142 ± 0.078 | 1.144 ± 0.064 | 0.806 |
| FL | |||
| Dmean (Gy) | 7.38 ± 2.95 | 5.94 ± 2.26 | <0.001 |
| V5 (%) | 39.68 ± 16.32 | 37.71 ± 14.82 | 0.041 |
| V10 (%) | 25.03 ± 10.24 | 15.79 ± 7.79 | <0.001 |
| V20 (%) | 11.00 ± 6.87 | 6.19 ± 3.72 | <0.001 |
| V30 (%) | 4.70 ± 4.18 | 3.42 ± 2.49 | 0.033 |
| Lungs | |||
| Dmean (Gy) | 9.91 ± 2.58 | 9.14 ± 2.56 | <0.001 |
| V5 (%) | 50.84 ± 11.72 | 49.58 ± 11.82 | 0.117 |
| V10 (%) | 35.09 ± 8.11 | 29.70 ± 7.52 | <0.001 |
| V20 (%) | 16.40 ± 5.86 | 13.82 ± 5.52 | 0.009 |
| V30 (%) | 7.45 ± 4.37 | 6.85 ± 3.72 | 0.039 |
| Heart | |||
| Dmean (Gy) | 17.12 ± 10.53 | 17.55 ± 10.68 | 0.298 |
| V5 (%) | 61.07 ± 35.27 | 60.96 ± 35.38 | 0.771 |
| V10 (%) | 53.46 ± 34.24 | 53.14 ± 34.46 | 0.766 |
| V20 (%) | 40.92 ± 29.67 | 40.00 ± 27.45 | 0.562 |
| V30 (%) | 22.47 ± 16.02 | 24.46 ± 17.11 | 0.078 |
| V40 (%) | 11.67 ± 9.91 | 13.57 ± 11.57 | 0.035 |
| Spinal cord | |||
| Dmax (Gy) | 38.82 ± 4.67 | 37.69 ± 5.87 | 0.600 |
| Dmean (Gy) | 11.99 ± 9.05 | 12.47 ± 9.53 | 0.142 |
Mean ± SD; P value was calculated by paired t-test. PTV, planning target volume; OARs, organs at risk; FL, functional lung; Dmax, maximum dose; Dmean, mean dose; Vx, volume of receiving = X Gy.
Figure 3Typical isodose dose distribution map of the radiotherapy planning for esophageal cancer patients. The functional lung (FL) are green areas. (A) Non-sparing planning (five-field fixed-beam IMRT); (B) five-field fixed-beam functional lung-sparing IMRT planning (5F-IMRT); (C) seven-field fixed-beam FL-sparing IMRT planning (7F-IMRT); (D) nine-field fixed-beam FL-sparing IMRT planning (9F-IMRT); (E) one-arc FL-sparing VMAT planning (1F-VMAT). (F) two-arc FL-sparing VMAT planning (2F-VMAT).
Dosimetric comparison in PTV and OARs between non-sparing (clinical treatment) planning and consistent beam directions of FL-sparing planning.
| OARs | 5F-IMRT | 2F-VMAT | P value |
|---|---|---|---|
| PTV | |||
| Dmax (Gy) | 58.19 ± 8.83 | 56.77 ± 8.75 | <0.001 |
| Dmean (Gy) | 52.54 ± 7.99 | 52.43 ± 7.96 | 0.225 |
| CI | 0.647 ± 0.106 | 0.711 ± 0.113 | 0.002 |
| HI | 1.152 ± 0.076 | 1.131 ± 0.071 | 0.019 |
| FL | |||
| Dmean (Gy) | 6.04 ± 2.32 | 5.64 ± 2.01 | 0.004 |
| V5 (%) | 37.61 ± 14.95 | 34.78 ± 13.32 | 0.027 |
| V10 (%) | 16.55 ± 7.65 | 13.27 ± 5.99 | 0.002 |
| V20 (%) | 6.52 ± 3.76 | 5.99 ± 3.57 | 0.037 |
| V30 (%) | 3.61 ± 2.53 | 3.22 ± 2.29 | 0.097 |
| Lungs | |||
| Dmean (Gy) | 9.18 ± 2.63 | 8.69 ± 2.43 | 0.004 |
| V5 (%) | 50.44 ± 13.05 | 46.03 ± 9.80 | 0.002 |
| V10 (%) | 30.51 ± 8.82 | 27.07 ± 7.52 | 0.001 |
| V20 (%) | 13.71 ± 5.43 | 13.20 ± 5.62 | 0.335 |
| V30 (%) | 6.86 ± 3.56 | 6.46 ± 3.27 | 0.104 |
| Heart | |||
| Dmean (Gy) | 17.38 ± 10.30 | 17.15 ± 10.34 | 0.302 |
| V5 (%) | 60.88 ± 35.20 | 61.51 ± 35.53 | 0.207 |
| V10 (%) | 53.10 ± 34.06 | 53.89 ± 33.48 | 0.518 |
| V20 (%) | 38.34 ± 25.07 | 39.56 ± 26.96 | 0.277 |
| V30 (%) | 23.80 ± 16.08 | 22.59 ± 15.86 | 0.050 |
| V40 (%) | 13.61 ± 11.30 | 12.17 ± 10.41 | 0.160 |
| Spinal cord | |||
| Dmax (Gy) | 40.01 ± 4.04 | 37.52 ± 6.01 | 0.209 |
| Dmean (Gy) | 12.23 ± 9.32 | 13.31 ± 9.89 | 0.002 |
Mean ± SD; P value was calculated by paired t-test. PTV, planning target volume; OARs, organs at risk; FL, functional lung; Dmax, maximum dose; Dmean, mean dose; CI, conformability index; HI, homogeneity index; Vx, volume of receiving ≥ X Gy; 5F-IMRT, five-field fixed-beam functional lung-sparing IMRT planning; 2F-VMAT, two-Arc functional lung-sparing VMAT planning.